US 11,787,846 B2
EphA2 T-cell epitope agonists and uses therefore
Walter J. Storkus, Glenshaw, PA (US); and Michael S. Kinch, Laytonsville, MD (US)
Assigned to UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, Pittsburgh, PA (US)
Filed by UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, Pittsburgh, PA (US)
Filed on Aug. 19, 2020, as Appl. No. 16/997,197.
Application 16/152,242 is a division of application No. 15/173,209, filed on Jun. 3, 2016, granted, now 10,131,699, issued on Nov. 20, 2018.
Application 14/069,208 is a division of application No. 13/355,343, filed on Jan. 20, 2012, granted, now 8,574,584, issued on Nov. 5, 2013.
Application 13/355,343 is a division of application No. 11/977,179, filed on Oct. 22, 2007, granted, now 8,114,407, issued on Feb. 14, 2012.
Application 16/997,197 is a continuation of application No. 16/152,242, filed on Oct. 4, 2018, granted, now 10,781,240.
Application 15/173,209 is a continuation of application No. 14/069,208, filed on Oct. 31, 2013, granted, now 9,359,402, issued on Jun. 7, 2016.
Application 11/977,179 is a continuation of application No. 11/233,796, filed on Sep. 23, 2005, granted, now 7,297,337, issued on Nov. 20, 2007.
Application 11/233,796 is a continuation of application No. 10/897,711, filed on Jul. 22, 2004, abandoned.
Claims priority of provisional application 60/491,046, filed on Jul. 30, 2003.
Prior Publication US 2021/0198333 A1, Jul. 1, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/17 (2006.01); C07K 7/06 (2006.01); C07K 7/08 (2006.01); C07K 14/47 (2006.01); C07K 14/705 (2006.01); G01N 33/50 (2006.01); G01N 33/569 (2006.01); A61K 39/00 (2006.01)
CPC C07K 14/4748 (2013.01) [A61K 38/1793 (2013.01); A61K 39/0011 (2013.01); C07K 7/06 (2013.01); C07K 7/08 (2013.01); C07K 14/47 (2013.01); C07K 14/705 (2013.01); G01N 33/505 (2013.01); G01N 33/5091 (2013.01); G01N 33/56966 (2013.01); G01N 33/56972 (2013.01); A61K 2039/55566 (2013.01); G01N 2333/5409 (2013.01); G01N 2333/57 (2013.01)] 22 Claims
 
1. An isolated peptide that consists of 9-35 amino acid residues, wherein said isolated peptide comprises the peptide of SLLGLKDQV (SEQ ID NO: 2, residues 961-969), GLTRTSVTV (SEQ ID NO: 2, residues 391-399), KLNVEERSV (SEQ ID NO: 2, residues 162-170) or MQNVIMNDMP (SEQ ID NO: 2, residues 55-63),
where said peptide of SLLGLKDQV (SEQ ID NO: 2, residues 961-969), GLTRTSVTV (SEQ ID NO: 2, residues 391-399), KLNVEERSV (SEQ ID NO: 2, residues 162-170) or MQNIMNDMP (SEQ ID NO: 2, residues 55-63):
(i) has up to one conservative amino acid substitution within the conservative substitution groups (a) S and T, (b) L, I and V, and (c) E and D; and
(ii) retains the ability to stimulate a T-cell immune response to EphA2 as determined by ELISPOT assay.